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INTRODUCTION
Traumatic injury is the leading cause of death in the United 
States among those aged ≤45 years.1,2 Most commonly, death 
is secondary to traumatic brain injury (TBI) or hemorrhage.3,4 
Tranexamic acid (TXA) inhibits fibrinolysis, strengthens clot 
formation, and reduces overall incidence of trauma-induced 
coagulopathy.5 TXA is a competitive inhibitor of plasminogen, 
which stops enzymatic breakdown of fibrin by plasmin, thereby 
facilitating secondary hemostasis.6
The CRASH-2 and CRASH-3 trials showed a significant 
reduction in mortality with administration within 3 hours 
of injury.7,8 However, concerns exist about the risk of venous 
thromboembolic (VTE) events (e.g., pulmonary embolism [PE], 
deep vein thrombosis [DVT]).9 Prehospital TXA administration 
was evaluated in the STAAMP trial, which showed mortality 
benefit in patients with severe shock who received TXA within 1 
hour of injury and benefit with dosages higher than standard.10
Objectives
This systematic review and meta-analysis aims to investigate the 
safety and efficacy of TXA use in acute traumatic injury through 
review of recent placebo controlled randomized clinical trials 
(RCTs) by assessing quantitative clinical outcomes in the pre-
hospital, in-hospital, and perioperative settings.
Population, Intervention, Comparator, and Outcomes
PICO 1
In adult trauma patients without TBI, is prehospital use of TXA 
associated with lower incidence of mortality, complication rates, 
and blood loss?
Background and Objectives: This systematic review and meta-analysis of randomized controlled trials (RCTs) aims to assess 
efficacy and safety of tranexamic acid (TXA) use in acute traumatic injuries.
Methods: PubMed and Cochrane libraries were searched for relevant RCTs published between January 2011 and January 3, 2021. 
Cohen’s Q Test for heterogeneous effects was used to determine the appropriateness of fixed versus random effects models.
Results: Twenty-two studies met inclusion criteria. Meta-analysis of relative risk of mortality between treatment and placebo groups 
in the in-hospital, and perioperative settings was not significant. However, the risk of mortality is significantly lower in the treatment 
versus placebo group when TXA was given as loading dose only. Ten of the 11 studies evaluating perioperative use of TXA included 
in systematic review found significantly lower blood loss in the treatment compared with placebo groups, but results of meta-analysis 
showed no significant difference. Results of meta-analysis indicate that the risk of venous thromboembolism (VTE) in the in-hospital 
treatment group is greater than that of the placebo. In subset analysis of studies using only a single loading dose, there were no 
significant differences in VTE.
Conclusions: Systematic review supports TXA benefits are most evident when given shortly after injury and meta-analysis supports 
TXA reduces mortality as a single loading dose. Systematic review supports perioperative use of TXA when large volume blood loss 
is anticipated. Meta-results showed no significant difference in risk of thromboembolism in single-dose TXA treatment compared with 
placebo. These findings suggest that TXA is safe and effective for control of traumatic bleeding.
Keywords: tranexamic acid prehospital use, tranexamic acid in-hospital use, tranexamic acid perioperative use, acute trauma, 
outcomes measures
From the *Department of Surgery, Division of Trauma and Surgical Critical Care, 
Kendall Regional Medical Center, Miami, FL; †Department of Mathematics, Nova 
Southeastern University, Davie, FL; and ‡Department of Surgery, University of 
South Florida, Tampa, FL.
Disclosure: The authors declare that they have nothing to disclose.
A.E. did study design and conception. S.R., A.L., I.Z., M.A., R.S., M.M., and A.E. 
did data collection, analysis, and interpretation. S.R., A.L., I.Z., M.A., R.S., M.M., 
and A.E. did article preparation and drafting. A.E., A.L., M.M., S.R., I.Z., R.S., and 
M.A. did critical revisions of article. All authors read and approved the final article.
S.R. and A.L. share first authorship on this work.
Supplemental digital content is available for this article. Direct URL 
citations appear in the printed text and are provided in the HTML and 
PDF versions of this article on the journal’s Web site (www.annalsofsurgery.com).
Reprints: Adel Elkbuli, MD, MPH, Department of Surgery, Kendall Regional 
Medical Center, Miami, FL, USA. E-mail: Adel.Elkbuli@hcahealthcare.com.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. This 
is an open-access article distributed under the terms of the Creative Commons 
Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it 
is permissible to download and share the work provided it is properly cited. The 
work cannot be changed in any way or used commercially without permission 
from the journal.
Annals of Surgery (2021) 4:e105
Received: 5 May 2021; Accepted 26 September 2021
Published online 8 November 2021
DOI: 10.1097/AS9.0000000000000105
Rowe et al • Annals of Surgery (2021) 4:e105 Annals of Surgery
2
PICO 2
In adult trauma patients without TBI, is in-hospital only use of 
TXA associated with lower incidence of mortality, complication 
rates, and blood loss?
PICO 3
In adult trauma patients without TBI, is perioperative only use 
of TXA associated with lower incidence of mortality, complica-
tion rates, and blood loss?
PICO 4
In adult trauma patients with TBI, is use of TXA associated with 
lower incidence of mortality, complication rates, and blood loss?
METHODS
Data Sources and Search Strategy
This study was completed according to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines.11 PubMed and Cochrane databases were searched 
for studies published between January 1, 2011, and January 3, 
2021. The following search keywords were included: “trauma” 
AND “tranexamic acid” AND “traumatic brain injury,” 
“trauma” AND “tranexamic acid” AND “blunt,” “trauma” 
AND “tranexamic acid” AND “penetrating” “trauma” AND 
“tranexamic acid” AND “prehospital.” Studies not published in 
the English language were excluded. Studies were first screened 
by title and abstract, then by full text. A final literature search 
was performed on January 3, 2021.
Study Selection and Eligibility Criteria
There were no limits on country of publication, TXA adminis-
tration setting, route, dosage, or patient follow up. While there 
were no limitations on patient age, included literature failed to 
report significant data regarding TXA administration in pedi-
atric trauma patients. Studies were excluded if quantitative 
clinical outcomes were not reported. Surveys, editorials, com-
mentary, and non-RCTs were excluded.
Risk of Bias and Quality of Evidence Assessment
Quality of evidence for all included studies was assessed using 
the Grading of Recommendations Assessment, Development, 
and Evaluation (GRADE) Working Group criteria.12 GRADE 
criteria were also utilized to determine risk of bias.
Data Collection Process
The initial literature search was performed by S.E.R., A.E., I.Z., 
and A.L. and later screened by article title and abstract for exclu-
sion. Authors S.E.R., A.E., I.Z., A.L., and M.A.A. performed sec-
ondary searches. The final literature search was conducted by A.E. 
and S.E.R. for data extraction from full-text RCTs. Any discrepan-
cies in screened and selected articles were reviewed and resolved 
by A.E., M.M., and S.E.R. The extracted data included publication 
year, patient population, patient demographics, the setting, route, 
and dosage of TXA, fraction of patients with TBI, blood loss, units 
of transfused blood, Glasgow Coma Scale (GCS), Injury Severity 
Score (ISS), mortality, complications, and patient follow-up time.
Outcome Measures
Primary outcome is in-hospital and 30-day mortality. Secondary 
outcomes included complications such as DVT, PE, or stroke. 
Tertiary outcomes included blood loss. Outcomes were further 
analyzed to determine the effect of ISS, TXA administration set-
ting/dosage, and by severity of TBI as evaluated by GCS.
Meta-analysis
Meta-analysis was performed in MS Excel 2010 and MATLAB 
2019b using our internal formulas and functions.13 In cases com-
paring occurrence rates of TXA-treated patients versus placebo, 
relative risk (RR) was chosen as the metric of comparison due to 
its relatively direct interpretation. In all cases, meta-analysis was 
performed only when more than three studies were included in a 
given subcategory. To properly assess RR, the number of events of 
interest in both TXA and Control groups needed to be at least one. 
In all cases, the Cohen’s Q test for heterogeneous effects was used 
to determine the appropriateness of fixed versus random effects 
models. Finally, all significance levels were defined as P < 0.05 
and all confidence intervals (CI) were calculated using 95% CI. 
Summary of population, intervention, comparator, and outcomes 
(PICO) questions and location of results are shown in Figure 1.
RESULTS
Systematic Review
Initial literature search of PubMed and Cochrane databases 
identified 1,205 publications. After removal of duplicates, 
873 studies remained. Studies not published in English were 
excluded. After screening by title/abstract, there were 375 stud-
ies. Non-RCTs were excluded, resulting in 67 trials for full-
text review. Twenty-two RCTs met inclusion criteria and were 
included for data extraction and meta-analysis (Fig. 2).8,10,14–33
Risk of Bias and Quality of Evidence Assessment
The quality of evidence was moderate (7 RCTs)16,18,19,24,27,30,32 
or high (15 RCTs)10,12–15,17,20–23,25,26,28,29,31 (Table S1a, http://
links.lww.com/AOSO/A85). The risk of bias was low: 3 RCTs 
reported small sample size, and 1 RCT reported 1 participant 
lost to follow up (Table S1b, http://links.lww.com/AOSO/A85).
Systematic Review of Prehospital and In-Hospital Use of TXA
There were only two studies which evaluated TXA given both 
prehospital and in-hospital.10,14 One study assessed use in non-
TBI trauma patients.10 The other study included only patients 
with TBI (Table S2, http://links.lww.com/AOSO/A85).14
Systematic Review of Prehospital and In-Hospital Use of 
TXA in Non-TBI
Guyette et al analyzed the STAAMP trial, which evaluated the 
effect of prehospital TXA on mortality among trauma patients 
with risk of hemorrhage.10 This large, multicenter RCT enrolled 
903 patients (Table S2, http://links.lww.com/AOSO/A85) from 
four US level 1 trauma centers, and had either prehospital hypo-
tension (SBP ≤ 90 mm Hg) or tachycardia (HR ≥ 110) <2 hours 
from injury.10 Patients were randomized to receive either 1 g of 
TXA or placebo by EMS.10 There was no difference in overall 
30-day mortality (8.1% vs 9.9%, P = 0.17), but subgroup anal-
ysis showed statistically significant difference when TXA was 
given within 1 hour of trauma (4.6% vs 7.6%; P < 0.002) or in 
cases of severe shock (18.5% vs 35.5%; P < 0.003) (Table S3, 
http://links.lww.com/AOSO/A85).10
Systematic Review of Prehospital and In-Hospital Use of 
TXA in TBI
Rowell et al evaluated field-use TXA in TBI among 966 
patients.14 Participants with moderate-severe TBI without 
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shock were recruited to the double-blind RCT from 20 United 
States and Canadian trauma centers (Table S2, http://links.
lww.com/AOSO/A85).14 Participants were randomized into 
three cohorts to receive 1 g prehospital TXA bolus plus an 8 
hours maintenance infusion (bolus plus maintenance group), 
2 g prehospital TXA bolus plus placebo infusion (bolus only 
group), or placebo bolus prehospital plus placebo infusion 
(placebo group).14 There was no statistically significant dif-
ference in positive neurological outcome (Glasgow Outcome 
Scale-Extended [GOSE] score > 4) at 6-month follow up 
(65% vs 62%; P = 0.84), in 28-day mortality (14% vs 17%; 
P = 0.26), or growth of intracranial hemorrhage (ICH) (16% 
vs 20%; P = 0.16) (Table S3, http://links.lww.com/AOSO/
A85).14
Systematic Review of In-Hospital Use of TXA
Nine studies evaluated TXA in the hospital setting.8,15,17,21–24,29,33 
Of these, 7 evaluated use in patients with TBI (Table S2, http://
links.lww.com/AOSO/A85).8,15,17,21,23,29,33 The dosing protocol 
for most of these studies included a loading bolus followed by 
maintenance infusion. Two studies only administered a one-time 
bolus of TXA.21,24
Systematic Review of In-Hospital Use of TXA in Non-TBI
Monsef Kasmaei et al randomized 106 patients with pelvic trauma 
to either 1 g intravenous TXA loading dose followed by 3 doses 
every 8 hours versus placebo.22 The main aim was blood loss 
reduction, evidenced by hemoglobin concentration (Tables S2 and 
S3, http://links.lww.com/AOSO/A85). There were significant dif-
ferences in hemoglobin concentrations between TXA and control 
groups at 48 hours (11.58 vs 10.25; P = 0.0001) and 72 hours 
(11.45 vs 9.83; P = 0.0001) after admission.22 No side effects were 
reported by either group after being discharged from the hospital.22
In the study conducted by Spinella et al, 149 patients were 
randomized to receive placebo, 2 g TXA, or 4 g TXA over 10 
minutes.24 There were no significant differences in baseline 
patient demographics, mortality (P = 0.81), or amount of blood 
products given after TXA administration (P > 0.05) between 
the groups.24 However, the difference in thromboembolic events 
approached significance with increasing TXA dosage (placebo: 
12.0%; 2 g: 26.5%; 4 g: 32.0%; P = 0.05).24
Systematic Review of In-Hospital Use of TXA in TBI
The CRASH-3 study examined the effect of TXA on TBI death 
in 9,127 patients randomly assigned to receive treatment or 
FIGURE 1. Summary of PICO questions and location of results. PICO, population, intervention, comparator, and outcomes.
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placebo within 3 hours of injury. They found no evidence of 
heterogeneity in the effect of TXA by patient age (P = 0.45).8 
Among the patients, the risk of head injury-related death was 
18.5% in the TXA group versus 19.8% with placebo (855 vs 
892 events, RR: 0.94; 95% CI: 0.86, 1.02).8 In sensitivity anal-
ysis, which excluded patients with a GCS=3 or bilateral unre-
active pupils at baseline, the risk was 12.5% versus 14% (485 
vs 525 events, RR: 0.89; 95% CI: 0.80, 1.00).8 Additionally, 
the CRASH-3 study found a reduction in the risk of head inju-
ry-related death with TXA in patients with mild-moderate head 
injury (RR: 0.78; 95% CI: 0.64, 0.95), but in patients with 
severe head injury they found no clear evidence of risk reduction 
(RR: 0.99; 95% CI: 0.91, 1.07) (Tables S2 and S3, http://links.
lww.com/AOSO/A85).8
Early treatment was more effective than later treatment in 
patients with mild-moderate head injury (P = 0.005), but no 
obvious difference in patients with severe head injury (P = 0.73) 
was found.8 In a regression analysis, when the effect of base-
line GCS was examined, they found TXA was more effective in 
less severely injured patients (P = 0.007) and reduced head inju-
ry-related deaths in those with reactive pupils (RR: 0.87; 95% 
CI: 0.77, 0.98).8 Overall, when stratified by time to treatment, 
no evidence of heterogeneity (P = 0.96) was recorded.8 The RR 
of head injury-related death, regardless of injury severity, with 
TXA was 0.96 (95% CI: 0.79, 1.17), 0.93 (95% CI: 0.85, 1.02), 
and 0.94 (95% CI: 0.81, 1.09) in patients randomly assigned to 
receive treatment within 1 hour, between 1 hour and 3 hours, 
and over 3 hours after injury, respectively.8
FIGURE 2. PRISMA flow chart for randomized controlled trials included in the systematic review and meta-analysis.
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Regarding complications, the CRASH-3 study did not find 
evidence of TXA increasing fatal or nonfatal stroke (RR: 1.08; 
95% CI: 0.71, 1.64). Risk of seizure was similar between TXA 
and placebo groups (RR: 1.09; 95% CI: 0.90, 1.33) (Table S3, 
http://links.lww.com/AOSO/A85).8
Jokar et al evaluated the effect of TXA on ICH 48 hours 
after injury in TBI with GCS > 8 (Table S2, http://links.lww.
com/AOSO/A85). Eighty patients were enrolled in the study and 
randomly assigned to be given either placebo or TXA (1 g bolus 
plus 1 g over 8 hours), and ICH was measured by CT scan. ICH 
volume expansion was significantly less in the TXA group (1.7 
vs 4.3 mL; P < 0.001).17 Mortality was not reported (Table S3, 
http://links.lww.com/AOSO/A85).
Participants in the study conducted by Mojallal et al 
received either 1 g TXA or placebo over 1 hour after admis-
sion and head CT (n = 120), within 8 hours of the trauma 
(Table S2, http://links.lww.com/AOSO/A85).21 There was no 
significant difference in mean cerebral hemorrhage volume 
at admission and after 24 hours between treatment and pla-
cebo groups (P = 0.207 and P = 0.824, respectively) (Table S3, 
http://links.lww.com/AOSO/A85).21 Similarly, there was no 
significant difference in in-hospital mortality (P = 0.236).21 It 
should be noted, however, that baseline ICH bleed types were 
not similar and 16 patients were lost to follow up in the TXA 
group and four in the control group.
Perel et al performed post-hoc analysis of 270 CRASH-2 TBI 
participants from 10 hospitals.23 Fewer patients in the TXA 
group had poor outcomes (significant hemorrhage growth, new 
intracranial hemorrhage, new focal cerebral ischemic lesions, 
need for neurosurgery, or death) compared with the placebo 
group (OR: 0.59; 95% CI: 0.37, 0.96).23 The adjusted OR for 
poor outcome was 0.57 (95% CI: 0.33, 0.98).23 Furthermore, 
there were no adverse events related to the study treatment.23
Yutthakasemsunt et al performed a 238-patient dou-
ble-blinded RCT evaluating TXA in reducing ICH for moder-
ate-severe TBI (GCS 4-12).29 Patients (≥16 years) were divided 
into a TXA arm (n = 120) receiving a 1 g loading dose over 
30 minutes and a maintenance dose of 1 g over 8 hours, and 
a placebo group with (n = 118).29 Primary outcome was ICH 
expansion. Progression of ICH, GOSE, and death were not sig-
nificantly different between the groups.29
Fakharian et al analyzed TXA (n = 74) versus placebo 
(n = 75) in TBI patients aged ≥ 15 (Tables S2 and S3, http://links.
lww.com/AOSO/A85).15 The TXA group received an in-hospital 
loading dose of 1 g and 1 g over 8 hours. There was no statistical 
difference in new bleeds (P = 0.210), hematoma expansion (RR: 
0.89; 95% CI: 0.55, 1.74), or need for surgery (RR: 0.67; 95% 
CI: 0.29, 1.55).15 Unfavorable outcomes at discharge (RR: 0.62; 
95% CI: 0.22, 1.46) and at 3 months (RR: 0.46; 95% CI: 0.16, 
1.26) were similar.15 Finally, mortality between both groups was 
similar (RR: 0.67; 95% CI: 0.12, 3.93).15 There was, however, a 
significant difference in the change in hemorrhage volume, with 
68.5% of the TXA patients experiencing a decrease compared 
with 50.7% in placebo (P = 0.03).15
Chakroun-Walha et al assessed TXA use in 180 TBI patients 
with no extracranial hemorrhage.33 Ninety-six patients were 
randomized to receive a loading dose of 1 g TXA, followed by 
1 g over 8 hours, but only 10% received TXA within 3 hours of 
injury.33 Transfusion requirements were similar through hospital 
day 7, and there was no significant difference in need for neu-
rosurgical intervention, mortality, or GOSE at 28 days.33 There 
was a significantly higher rate of PE in the TXA group (11.5% 
vs 2.4%; P = 0.02).33
Systematic Review of Perioperative Use of TXA
A total of 11 studies evaluated perioperative TXA use (Tables 
S2 and S3, http://links.lww.com/AOSO/A85).16,18–20,25–28,30–32 
Of these, seven administered only one preoperative TXA 
bolus.16,18,20,26,28,31,32 Three administered two identical doses of 
TXA.25,27,30 One gave a loading dose followed by maintenance 
dose of TXA.19
Tengberg et al recruited 72 patients to their RCT evaluating 
perioperative TXA in unstable extracapsular hip fractures.26 
Patients were randomized to receive TXA (n = 33) or placebo 
(n = 39).26 The TXA cohort was given a preoperative bolus of 
1 g TXA and a postoperative infusion of 3 g over 24 hours.26 
The TXA cohort had a 90-day mortality rate of 39% and the 
placebo cohort had a mortality rate of 10.2% (P = 0.07).26 The 
TXA cohort had a recorded blood loss of 1,529.6 mL while 
the placebo cohort had a recorded blood loss of 2,100.4 mL 
(P = 0.029).26
Watts et al evaluated perioperative TXA use in 138 patients 
undergoing arthroplasty for low energy isolated femoral neck 
fracture, divided into TXA (n = 69) or placebo (n = 69) groups 
(Table S2, http://links.lww.com/AOSO/A85).27 The TXA cohort 
received a perioperative dose of 15 mg/kg TXA and a second 
dose after wound closure.27 Blood loss in the TXA cohort was 
lower throughout postoperative days (POD) 1 (731 vs 973 mL; 
P = 0.01), 2 (830 vs 1124 mL; P = 0.0002), and 3 (902 vs 
1205 mL; P = 0.0005) (Table S3, http://links.lww.com/AOSO/
A85).27
Xie et al assessed TXA in patients undergoing calcaneal frac-
ture surgery, randomized into 2 cohorts of 45 patients.28 The 
treatment group received a perioperative dose of 15 mL/kg.28 
The control group demonstrated lower incidence of wound 
complications (3 vs 10 patients, 7.3% vs 23.8%, P = 0.036).28 
Vascular events such as DVT, MI, and CVA were similar (Table 
S3, http://links.lww.com/AOSO/A85).28 There were significant 
differences in postoperative blood loss between the two groups 
(110.0 mL in TXA vs 320.0 mL placebo; P < 0.001).28
Zhang et al evaluated TXA use in patients receiving nail 
fixation of intertrochanteric femur fractures.30 They recruited 
122 participants, randomized into two groups of 61. The treat-
ment group received two doses of 1 g TXA over 10 minutes.30 
There was no significant difference in mortality between TXA 
and placebo (1.6% vs 3.3%; P = 1.000). The TXA group had 
lower blood loss (712.11 mL) compared with the placebo group 
(1,103.5 mL; P < 0.001).30
Zhou et al also evaluated TXA in intertrochanteric fractures.31 
Fifty patients were randomized to receive 1 g TXA before prox-
imal femoral surgery and 50 received placebo.31 There were no 
statistical differences between the groups for DVT (P = 0.65) or 
PE (P = 0.31). Blood loss was significantly lower in TXA group 
(563.37 vs 819.25 mL, 95% CI: −349.49, 162.27; P < 0.01) 
(Table S3, http://links.lww.com/AOSO/A85).31
Lack et al evaluated perioperative TXA in open reduction 
and internal fixation (ORIF) of acetabular fractures.19 They 
recruited 88 patients from 2 US level 1 trauma centers, ran-
domized to receive either TXA (n = 42) or placebo (n = 46) 
in a 10 mg/kg bolus 30 minutes before surgery, plus 10 mg/kg 
IV intraoperatively (Tables S2 and S3, http://links.lww.com/
AOSO/A85).19 There was no significant difference in blood loss 
(753 vs 533 mL; P = 0.061), transfusion rate (50% vs 32.6%; 
P = 0.097), or transfusion requirements (average of 2.65 vs 
2.36 units; P = 0.522) (Table S3, http://links.lww.com/AOSO/
A85).19Khiabani et al examined perioperative TXA in ORIF for 
bilateral displaced mandibular fractures18 from a center in Iran 
(Table S2, http://links.lww.com/AOSO/A85). Participants were 
randomized into equal-sized cohorts receiving either 20 mg/kg 
of TXA or placebo prior to surgery.18 They found that mean 
blood loss was significantly lower in the TXA group (360.57 
± 173.5 mL and 560.9 ± 248.07 mL, respectively; P = 0.008) 
(Table S3, http://links.lww.com/AOSO/A85).18
Lei et al evaluated perioperative TXA in surgical repair of 
traumatic intertrochanteric fracture; 77 participants were 
recruited to this single-blind study and randomized to receive 
either 1 g of TXA or placebo.20. There was significantly lower 
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estimated blood loss on POD-3 (279.35 ± 209.11 vs 417.89 
± 289.5; P = 0.049) and transfusion rate (28.20% vs 56.09%; 
P = 0.01) in the TXA group (Table S3, http://links.lww.com/
AOSO/A85).20
Spitler et al randomized patients to receive either TXA or 
placebo for hip or pelvis ORIF; patients received a 15 mg/kg 
preoperative loading dose and a 15 mg/kg dose 3 hours after 
initial dose.25 When excluding cell saver, total blood loss was 
higher in the control group (952 vs 1,325 mL; P = 0.028) (Table 
S3, http://links.lww.com/AOSO/A85).25 When including cell 
saver volumes, total blood loss remained higher in the control 
group (1,048 vs 1,396 mL; P = 0.046).25 The average drop in 
hematocrit from preoperative to POD-1 was greater (P = 0.021) 
in the control group.25 The average drop from preoperative to 
POD-2 was also greater in the control group (P = 0.026; TXA 
= 25.37, placebo = 27.97).25 There were no differences in major 
complications.25
Batibay et al analyzed the safety and effectiveness of TXA 
versus placebo administration in the setting of isolated trau-
matic tibial-fibular fractures requiring fixation via intra-
medullary nailing.32 This study excluded polytrauma, those 
requiring open reduction or other orthopedic intervention, 
Gustilo/Anderson type 2 or 3 open fractures, any abnormal 
INR, and coagulopathies.32 The study included 35 patients in 
both the control and TXA cohorts who were evaluated over 
a 12-week follow-up period.32 The TXA cohort received a 
10 mg/kg IV bolus 30 minutes prior to first incision.32 The Hb 
levels at 24 hours (11.38 vs 10.34; P = 0.0067) and 48 hours 
(10.78 vs 9.98; P = 0.0023) were significantly higher in the 
TXA group.32
Dakir et al assessed the effectiveness of a single 10 mg/kg dose 
of TXA versus placebo 15 minutes preoperatively in minimiz-
ing blood loss in patients undergoing maxillofacial traumatic 
fractures.16 Their RCT measured Hb preoperatively and post-
operatively at 4, 24, and 48 hours intervals, and both intra 
and postoperative blood loss in 12 male patients (ages 20–40 
years).16 They reported statistically significant reduction in 
blood loss in the TXA group (489.17 vs 900.83 mL; P < 0.001) 
(Table S3, http://links.lww.com/AOSO/A85).16
Meta-Analysis
Meta-Analysis of Mortality Risk
Only two studies had the treatment cohort receive both pre- 
and in-hospital TXA.10,14 This was insufficient to perform a 
meaningful meta-analysis. Thus, only in-hospital and perioper-
ative mortality rates underwent meta-analysis (Tables 1 to 4). 
In both, Cohen’s Q was not significant (Table 1), indicating a 
fixed effects model was sufficient. There is insufficient evidence 
to conclude a difference between TXA and placebo mortality 
rates in either setting (in-hospital 95% CI: 0.86, 1.02, perioper-
ative 0.76–2.45) (Figure S1a, http://links.lww.com/AOSO/A84). 
Considering only in-hospital TBI studies, this does not change. 
A direct comparison of the means of the two meta-groups was 
not significant (Z-test, P = 0.2124), indicating there is not suf-
ficient evidence to show a difference in RR between in-hospital 
and perioperative settings (Figure S1a, http://links.lww.com/
AOSO/A84).
In both single-dose and loading and maintenance subcatego-
ries, Cohen’s Q was not significant, indicating a fixed effects 
model was sufficient. There is sufficient evidence the risk of 
mortality in TXA-administered patients is smaller than that of 
the placebo (95% CI: 1.09, 2.04) (Table  1).16,18,20,21,24,26,28,31,32 
However, in the Loading and Maintenance subcategory, there is 
insufficient evidence of a difference between TXA and placebo 
mortality rates (95% CI: 0.87, 1.02).8,14,15,17,19,22,23,29,33
When all studies are considered irrespective of setting or 
administration, no significant difference in mortality was found 
between Placebo and TXA.
Meta-Analysis of Risk of General Complications
For the same reasons as above, only differences between in-hos-
pital and perioperative settings were considered. In periopera-
tive, Cohen’s Q was not significant, indicating a fixed effects 
model was sufficient (Table  2). However, for in-hospital, 
Cohen’s Q was significant, indicating a random effects model 
was needed. There is insufficient evidence to conclude a dif-
ference between TXA and placebo complication rates in both 
settings (in-hospital 95% CI: 0.26, 1.31; perioperative 95% 
CI: 0.86, 2.11) (Figure S1b, http://links.lww.com/AOSO/A84). 
A direct comparison of the means of the two meta-groups was 
not significant (Z-test, P = 0.0779), indicating there is insuffi-
cient evidence to show a difference in RR between the in-hospi-
tal and perioperative settings.
In the single-dose subcategory, Cohen’s Q was not significant, 
indicating a fixed effects model was sufficient. However, for the 
Loading and Maintenance subcategory, Cohen’s Q was signif-
icant, indicating a random effects model was needed. In both 
cases, there is not sufficient evidence to conclude a difference 
between TXA and placebo general complication rates in either 
dosing subcategory (single-dose 95% CI: 0.65, 1.70, loading 
and maintenance 0.33–1.27) (Table 2; Figure S1b, http://links.
lww.com/AOSO/A84). A direct comparison of the means of the 
two meta-groups was not significant (Z-test, P = 0.2536), indi-
cating there is not sufficient evidence to show a difference in RR 
between the dosing subcategories.
When all studies are considered irrespective of setting or 
administration, no significant difference in incidence of compli-
cations was found between placebo and TXA.
Meta-Analysis of Risk of Venous Thromboembolism
In both cases, Cohen’s Q was not significant, indicating a fixed 
effects model was sufficient. The 95% CI for the In-Hospital 
setting is entirely below one (95% CI: 0.44, 0.90), indicating 
there is sufficient evidence the risk of VTE in TXA-administered 
patients is greater than in the placebo (Figure S1c, http://links.
lww.com/AOSO/A84). There is insufficient evidence for that 
conclusion in the perioperative setting (95% CI: 0.43, 1.83) 
(Table 3).
There were sufficient studies reporting VTE rates for 
meta-analysis only in the single-dose subcategory. Cohen’s Q 
was not significant, indicating a fixed effects model was suffi-
cient. The meta-analysis 95% CI contains one (95% CI: 0.54, 
1.09), indicating that there is insufficient evidence to conclude a 
difference between TXA and placebo general complication rates 
in this dosing subcategory (Figure S1c, http://links.lww.com/
AOSO/A84).
When all studies are considered irrespective of differences 
in setting or administration, with the risk of VTE in placebo 
patients was found to be 0.68 times that of TXA-administered 
patients (95% CI: 0.49, 0.93).
Meta-Analysis of Risk of Infection
When all studies are considered irrespective of setting or admin-
istration, no significant difference in incidence of infection was 
found between placebo and TXA. Due to insufficient number 
of usable trials, we were unable to perform any comparison 
meta-analyses of pre- versus in-hospital timing or dose on infec-
tion risk.
Meta-Analysis of Risk of Stroke
There was an insufficient number of usable trials to perform 
comparison meta-analyses on stroke risk. When all studies are 
considered irrespective of setting or administration, no signifi-
cant difference in stroke incidence was found between placebo 
and TXA.
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Meta-Analysis of Blood Loss
All studies with Blood Loss values that included standard devi-
ations were in the Perioperative setting.16,18–20,26,28,30,31 Cohen’s Q 
was significant (P < 0.0001), indicating the need for a random 
effects model. The 95% CI for the resulting difference between 
the placebo and TXA means contains zero (95% CI: –22, 344), 
indicating there is insufficient evidence to show that blood loss 
for the TXA group differs from the placebo group (Table  4; 
Figure S1d, http://links.lww.com/AOSO/A84). Analysis of the 
five studies that evaluated TXA use in surgical treatment of 
traumatic hip or pelvic fractures showed meta-CI containing 
zero (95% CI: –20, 367). When considering the single-dose sub-
set of these studies, the result does not change. No other dosing 
subsets had enough for meaningful meat-analysis.
DISCUSSION
This systematic review and meta-analysis included 22 RCTs 
evaluating TXA use in prehospital, in-hospital, and periopera-
tive settings. Main outcomes assessed were mortality, complica-
tions, and blood loss.
The systematic review found that in adults with non-TBI 
traumatic injury, prehospital TXA showed significant mortality 
benefit when given ≤1 hour after injury.10 In the lone study of 
TXA in TBI given prehospital, there was no significant differ-
ence in outcome, mortality, or ICH volume.14 The CRASH-3 
trial showed significant mortality benefit with early administra-
tion of TXA in mild-moderate, but not severe, TBI.8 There was 
no significant difference in in-hospital mortality between TXA 
and placebo groups.21,33
We also found that most studies assessing perioperative TXA 
found significant reduction in intraoperative blood loss com-
pared with placebo.16,18,20,25–28,30–32 One study reported no signif-
icant difference in blood loss.19 Meta-analysis showed a 178 mL 
difference between the Control and TXA, with a 95% Student’s t 
CI of (–21.6, 343.5), indicating there is not sufficient evidence to 
show the blood loss for the TXA group differs from the placebo 
group. There was a variable effect on ICH volume expansion in 
TXA compared with placebo. Two studies reported significantly 
less ICH expansion, while two others reported no significant 
difference.15,17,23,29
Meta-analysis of comparison of RR of mortality between 
treatment and placebo groups in in-hospital and perioperative 
settings was not significant. However, when considering studies 
which only administered one loading TXA bolus, the meta-CI 
was >1, indicating risk of mortality is significantly lower in the 
treatment group.
Meta-analysis results indicate the risk of VTE in the treat-
ment group is greater than in the placebo in in-hospital setting. 
However, there is not sufficient evidence for that conclusion in 
perioperative setting, nor is there sufficient evidence to show a 
difference in RR between in-hospital and perioperative settings. 
There was no significant difference in RR in single-dose TXA, 
TABLE 1.









Cohen’s Q  
P Value




All studies 12 5427 5320 0.2171 0.94 (0.87, 1.02)
Administration Site In-hospital 8 5227 5111 0.4839 0.94 (0.86, 1.02)
In-hospital, TBI only 6 5128 5011 0.2912 0.94 (0.86, 1.02)
Perioperative 4 200 209 0.1001 1.36 (0.76, 2.45)
Dosing Single dose 6 570 532 0.2393 1.49 (1.09, 2.04)
Loading and maintenance 6 5384 5276 0.5038 0.94 (0.87, 1.02)
TXA indicates tranexamic acid.
TABLE 2. 









Cohen’s Q  
P Value




All studies 9 683 674 0.0127 0.61 (0.32, 1.16)
Administration site In-hospital 4 423 414 0.0038 0.59 (0.26, 1.31)
Perioperative 5 260 260 0.8724 1.34 (0.86, 2.11)
Dosing Single dose 4 475 439 0.0823 1.05 (0.65, 1.7)
Loading and maintenance 5 735 723 0.0080 0.65 (0.33, 1.27)
TXA indicates tranexamic acid.
TABLE 3.









Cohen’s Q  
P Value




All studies 9 5106 5002 0.4698 0.68 (0.49, 0.93)
Administration site In-hospital 4 4844 4737 0.1649 0.63 (0.44, 0.9)
Perioperative 5 262 265 0.7684 0.89 (0.43, 1.83)
Dosing Single dose 6 576 544 0.2269 0.76 (0.54, 1.09)
TXA indicates tranexamic acid; VTE, venous thromboembolism.
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regardless of setting. Unfortunately, there were not enough stud-
ies reporting VTE rate in other dosing protocols.
While a few prior studies have analyzed the combined results 
of recent TXA RCTs, to our knowledge this is the largest sys-
tematic review and meta-analysis of 22 studies. Other reviews 
include up to 12 studies.34–39 This study includes comparative 
analysis of administration setting/dosing and type of injury. 
Although other systematic reviews and meta-analyses, such as 
the publication by Almuwallad et al, have attempted to eluci-
date the effect of prehospital TXA use, to our knowledge, no 
other study includes only randomized controlled trials (RCTs).40 
Almuwallad et al included a total of four studies: only one RCT, 
one retrospective cohort, and two prospective cohorts.40
Current recommendations and guidelines are often vague and 
inconclusive, partly due to gaps in the literature reporting strong 
and consistent evidence for TXA in various traumatic settings 
and injury types. Furthermore, because trials like the CRASH 
studies were conducted outside the United States, similar studies 
should be conducted in the United States to draw more conclu-
sive evidence and provide clearer guidelines. The 2017 Eastern 
Association for the Surgery of Trauma (EAST) guidelines for 
damage control resuscitation and severe traumatic hemorrhage 
recommended TXA for in-hospital use.41
The findings of the systematic review suggest there is some 
mortality benefit associated with early TXA in trauma. These 
results highlight the need for clear, concordant guidelines for 
TXA in trauma. The inclusion of only RCTs provides stronger 
evidence and limits risk of bias. Understanding the importance 
of TXA with factors such as setting, demographics, GCS, dosage, 
and timing is crucial.40 Identification of key injury patterns and 
development of detailed guidelines may significantly improve 
patient outcomes. This study may assist in valuation of TXA 
in trauma, or at least provide indications for further research.
Limitations
There is a large heterogeneity present for numerous data 
points reported within the RCTs in this systematic review and 
meta-analysis; notably, variation in VTE screening and mixed 
reporting and variability of the inclusion criteria. While this has 
been accounted for in our meta-analysis, there remains some 
degree of discrepancy in the reporting criteria and technical 
definitions of VTE in general. Furthermore, analysis of variables 
such as race, ISS, GCS, LOS, follow up, and factors related to 
blood loss, such as mean units of blood transfused, was not fea-
sible due to underreporting. Similarly, analysis of mechanism of 
injury was not feasible due to low reporting. Heterogeneity in 
injury type also exists; while this has some advantage, in that it 
may allow our findings to be more generalizable in a variety of 
trauma situations, the inconsistency in reporting mechanism of 
injury makes sophisticated analysis difficult. Additionally, only 
two studies evaluated prehospital TXA, which limited robust 
assessment. Outcome reporting among the included studies var-
ied; some reported overall adverse events while others assessed 
specific complications. Intrinsic limitations of contributing stud-
ies such as, but not limited to, lack of diversity in age, race, 
and gender may have led to findings which cannot be attributed 
to TXA use. Moreover, mortality included deaths occurring 
within 30 days of intervention in some studies while others only 
reported in-hospital mortality. Of note, included RCTs were 
published in various international journals, with varying impact 
factors. There were also differences in the number of patients 
within studies. Despite our aim to include all RCTs on TXA use 
in traumatic injury, studies such as the CRASH-3 trial enrolled 
patients on a much larger scale than others. Consequently, a 
larger proportion of patients and results were obtained from the 
CRASH-3 trial.
CONCLUSIONS
The systematic review of TXA indicates the benefits of this 
intervention appear most evident when given shortly after trau-
matic injury. The systematic review also supports the value of 
TXA in reducing intraoperative blood loss and evidence indi-
cates it could provide more favorable outcomes when used in 
emergent settings in which large volumes of blood loss are antic-
ipated. The meta-analysis showed TXA used as a single dose 
was associated with improved mortality. Meta-analysis of TXA 
used in a single dose showed no significant difference in risk of 
VTE or other complications compared with placebo. Cohesive 
guidelines on the use of TXA are lacking; the findings of this 
study may aid in the development of algorithms for identifying 
patients who may benefit from TXA use.
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